Keros Therapeutics, Inc. (KROS) News
Follow Keros Therapeutics, Inc. (KROS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) NASDAQ:KROS, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide
NEWS | Sep 29, 2026, 12:09 PM UTC
L
Keros to Receive $20M Milestone After First Patient Dosed in ELRiSE MF Phase 3 Trial
Keros expects a $20 million development milestone payment from Takeda following the first patient dosing in the ELRiSE MF Phase 3 trial.Key Highlights:Original SEC Filing: Keros Therapeutics, Inc. [ KROS ] - 8-K - Sep. 2
REGULATION | Sep 29, 2026, 12:03 PM UTC
L
Keros Therapeutics doses first patient in Phase 2 rinvatercept trial; initial data expected H1 2027
Keros Therapeutics dosed the first patient in its Phase 2 trial of rinvatercept for Duchenne muscular dystrophy and expects initial data in the first half of 2027.Key Highlights:Original SEC Filing: Keros Therapeutics, I
REGULATION | Sep 28, 2026, 12:04 PM UTC
L
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Initial data expected in the first half of 2027LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) NASDAQ:KROS, a clinical-stage biopharmaceutical company focused on developing and com
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Keros Therapeutics may offer up to $350 million of securities
Keros Therapeutics, Inc. filed with the SEC to offer securities with an aggregate offer size of up to $350 million. The filing is related to its NASDAQ-listed company.
REGULATION | Sep 10, 2026, 08:12 PM UTC
L
KROS files mixed shelf registration
KROS filed a Form S-3 for a mixed shelf.
EQUITY | Sep 10, 2026, 08:10 PM UTC
L
Keros Therapeutics launches $5M share buyback after $20M milestone payment
Keros Therapeutics launched a $5 million share repurchase program after receiving a $20 million development milestone payment under a license agreement with Takeda Pharmaceuticals USA, following the dosing of the first p
EQUITY | Sep 08, 2026, 09:01 PM UTC
M
Keros approves $5 million buyback after Takeda milestone
Keros announced a $5 million share repurchase program after receiving a $20 million development milestone from Takeda. It said cash supports operations into the second half of 2028.
REGULATION | Sep 08, 2026, 08:15 PM UTC
L
Keros Therapeutics authorizes $5 million share repurchase
Keros Therapeutics (KROS) announced a $5 million share repurchase authorization.
EQUITY | Sep 08, 2026, 08:01 PM UTC
L
KROS - Keros Therapeutics Reports Second Quarter 2026 Financial Results
KROS - Keros Therapeutics Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 03, 2026, 08:01 PM UTC
H
Keros Therapeutics Receives $20M Milestone Payment
Keros Therapeutics gets $20M payment from Takeda
EQUITY | Jul 30, 2026, 08:06 PM UTC
H
KROS Receives Milestone Payment
KROS receives development milestone payment
EQUITY | Jul 30, 2026, 08:01 PM UTC
L
KROS Keros Therapeutics - keith regnante resigns as CFO effective August 3, 2026 - SEC filing - Appoints annita tanini interim Principal fin
KROS Keros Therapeutics - keith regnante resigns as CFO effective August 3, 2026 - SEC filing - Appoints annita tanini interim Principal financial officer effective August 4, 2026 - SEC filing
REGULATION | Jul 22, 2026, 08:03 PM UTC